Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Why pensions still go missing in divorce settlements
For specialist divorce lawyers, the importance of properly addressing pension assets is now widely understood. Whilst efforts have been made to raise
Active portfolio management: Why active insurers are fitter
Amid the noise generated by each day’s operational activities, how can insurers be confident they’re on track to achieve their strategic goals? The sh
TPR clarifies responsible use of AI in workplace pensions
"Trust is the most valuable asset in our system" – TPR CEO urges safe and responsible adoption of artificial intelligence (AI) in members' intere

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.